Please assess the completion status of the following clinical trial:

Trial Title: ACT34-CMI -- Adult Autologous CD34+ Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Canadian Cardiovascular Society (CCS) functional class III or IV chronic refractory angina~* subjects without control of their angina symptoms, in spite of maximal tolerated doses of anti-anginal drugs, must be on optimal therapy for their angina and on a stable anti-anginal medication regimen for at least 1 month prior to entering the screening period of the study~* identified as unsuitable for conventional revascularization~* recent coronary angiogram (within the last 12 months) to document the coronary anatomy and to verify the revascularization procedures~* subjects must have objective evidence of inducible ischemia or viable myocardium in the potential target injection zone~* a left ventricular ejection fraction equal to or greater than 25% by ECHO or single photon emission computed tomography (SPECT) at screening~* subjects must experience at minimum an average of 7 angina or anginal equivalent episodes per week~* subjects must be able to complete a minimum of 3 minutes but nor more than 10 minutes on a treadmill following the Modified Bruce Protocol~* subjects must experience angina or anginal equivalent episodes during the screening exercise treadmill test~* female subjects must either be no longer capable of reproduction or using medically valid contraception to prevent pregnancy during the study~* subjects must be willing and able to comply with specified follow-up evaluations~Exclusion Criteria:~* predominant congestive heart failure~* myocardial infarction within 60 days of treatment~* successful or partially successful coronary revascularization procedures (any vessel) within 6 months of study enrollment~* placement of a bi-ventricular pacemaker for cardiac resynchronization therapy (CRT) for heart failure in the past 90 days~* documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment~* history of moderate to severe aortic stenosis or severe aortic insufficiency; severe mitral stenosis or severe mitral insufficiency~* prosthetic aortic valve replacement~* evidence of any life-threatening arrhythmia that requires intervention on the 24-hour Holter monitor. Life-threatening arrhythmia that is successfully treated with an implantable cardioverter defibrillator (ICD) is not exclusionary.~* splenomegaly and/or severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (ie, severe chronic obstructive pulmonary disease, renal failure or cancer \[exceptions: in-situ skin cancer or fully removed skin cancer other than melanoma, in-situ cervical cancer, or cancer free for 5 years with no history of a stem cell transplant\])~* sickle cell disease or sickle cell trait~* platelet count greater than 10% above the upper limit of normal or a platelet count below 100,000 if on Clopidogrel or 50,000 without Clopidogrel~* hematocrit \<30%~* serum creatinine \>2.5 mg/dL~* any clinically significant laboratory abnormality on screening laboratories~* currently enrolled in another IDE or IND that has not completed the protocol required primary follow-up period (excludes 15 year follow up of gene therapy trials)~* history of alcohol or drug abuse within 3 months of screening~* joint or peripheral vascular disease or neurologic disease that severely limits treadmill walking~* chronic obstructive pulmonary disease that severely limits walking or FEV1 \<30% predicted~* females who are pregnant or lactating~* female subjects who are capable of reproduction and will not use medically valid contraception to prevent pregnancy during the study~* subjects who test positive for HIV, hepatitis B or hepatitis C, or are on chronic immunosuppressive medications or have had a prior stem cell transplant~* subjects with a known hypersensitivity to E. coli-derived proteins, or to any component of Neupogen (Filgrastim) or G-CSF~* subjects who have a significant psychiatric disorder or mental disability that could interfere with the subject´s ability to provide informed consent and/or comply with protocol procedures

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CLBS14: Low-Dose Group (Type: EXPERIMENTAL): 10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight
- CLBS14: High-Dose Group (Type: EXPERIMENTAL): 10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight
- Placebo injection (Type: PLACEBO_COMPARATOR): 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).